Blueprint Medicines Corp.

Blueprint Medicines Corp.

Blueprint Medicines Corp.

Overview
Date Founded

2008

Headquarters

45 Sidney Street,Cambridge, MA 02139

Type of Company

Public

Employees (Worldwide)

383

Industries

Biotechnology
Medical Products & Equipment
Hospitals & Patient Services
Medical Support Services

Company Description

Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

Contact Data
Trying to get in touch with decision makers at Blueprint Medicines Corp.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer, President

Chief Financial Officer

Chief Operating Officer

Chief Commercial Officer

Executive Vice President, Chief Legal & Compliance Officer

Chief Scientific Officer

Chief People Officer

Chief Medical Officer

President, Research & Development

Vice President-Finance & Controller

Board of Directors

Executive Chairman at Surface Oncology, Inc.

President & Chief Executive Officer & Director at Lexicon Pharmaceuticals, Inc.

Managing Member at Staurus Pharma LLC

Co-Founder at EQRx, Inc.

Director & Quick Family Chair-Center for Sarcoma & Bone Oncology at Dana-Farber Cancer Institute, Inc.

Former Director of Finance at Bristol-Myers Squibb Company

Chief Executive Officer at Myovant Sciences, Inc.

Chief Executive Officer, President at Blueprint Medicines Corp.

Physician at The Brigham & Women's Hospital, Inc.

Paths to Blueprint Medicines Corp.
Potential Connections via
Relationship Science
You
Blueprint Medicines Corp.
Owners & Shareholders
Details Hidden

Cadian Capital Management manages funds which seek long-term capital appreciation from investments in equity securities of companies in the global telecommunications, media and technology sectors as well as in consumer, healthcare, industrials, financial services and technology and other related sectors. To implement the above strategy, the firm focuses on fundamental stock research and selection through a disciplined upside/downside analysis. Cadian Capital Management takes a value-oriented approach to the sectors in which the funds invest, drawing upon the deep sector experience of their personnel across geographies and asset classes. They focus on seeking to minimize market and other systemic risks to the funds’ portfolios. The firm aims conservative net beta exposure through alpha generative long and short positions.

Details Hidden

VGI is an active, long-term manager which aims to achieve maximum capital appreciation while mitigating general market risk by employing a hedged approach and taking short positions as well as long positions. The firm performs fundamental analysis to select investments primarily in public equity securities, but also in private equity and other financial instruments. They typically invest in companies located around the world that operate in a wide range of industries.

Details Hidden

HCA seeks long-term, risk-adjusted returns through bottom-up analysis and fundamental proprietary research. As part of their bottom-up analysis, they perform both qualitative and quantitative assessments of potential investments with a particular focus on opportunities upon which it can gain insights and discover value in an ever-changing world. Their research process employs fundamental, quantitative, and qualitative analysis, including cyclical analysis. The firm generally focuses on publicly-listed (or similarly liquid) investment opportunities across multiple industries, but it may also participate in private (or otherwise less liquid) investment opportunities. HCA invests globally with a particular focus on companies or assets having substantial relations with Asia

Recent Transactions
Details Hidden

Blueprint Medicines Corp. issued USD Common Stock

Details Hidden

Blueprint Medicines Corp. issued USD Common Stock

Details Hidden

Blueprint Medicines Corp. issued USD Common Stock

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Escrow Agent

Advised onBlueprint Medicines Corp. issued USD Common Stock

Underwriter

Advised onBlueprint Medicines Corp. issued USD Common Stock

Underwriter

Advised onBlueprint Medicines Corp. issued USD Common Stock

Legal Advisor

Advised onBlueprint Medicines Corp. issued USD Common Stock

Associate

Advised onBlueprint Medicines Corp. issued USD Common Stock

Associate

Advised onBlueprint Medicines Corp. issued USD Common Stock

Advisors & Consultants
Legal Advisor

National Co-Chair, Life Sciences Practice at Goodwin Procter LLP

Clients

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

Ipsen SA manufactures pharmaceutical products for oncology, neuroscience and rare diseases. It operates through following segments: Specialty Care and Consumer Healthcare. The Specialty Care segment focuses on Oncology with Somatuline, a somatostatin analog for the treatment of neuroendocrine tumors; Cabometyx, the single-agent treatment with significant improvement across all key efficacy endpoints in second-line renal cell carcinoma; Onivyde, a differentiated product with overall survival benefit addressing a high unmet medical need in pancreatic cancer; and Decapeptyl, an established and growing product in Europe and China for prostate cancer and Rare Diseases with Nutropin, a liquid formulation of recombinant human growth hormone and Increlex, a recombinant insulin-like growth factor of human origin. The Consumer Healthcare segment include brands such as Smecta, a naturally extracted purified clay for the symptomatic treatment of acute diarrhea; Tanakan, a standardized extract from the leaves of Ginkgo biloba for the treatment of various neurological and neuro-sens or ial disorders; Forlax, an osmotic laxative indicated for the symptomatic treatment of constipation in adults and children; and Fortrans, a colon cleansing solution indicated for patients in preparation for endoscopic, radiological examinations or colonic surgery. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France.

Cstone Pharmaceuticals Co. Ltd. engages in the research and development of highly complex biopharmaceutical products. It offers cancer therapeutics with a special focus on immuno-oncology based combination therapies. The company was founded on December 2, 2015 and is headquartered in Shanghai, China.

Key Stats and Financials As of 2019
Market Capitalization
$5.5B
Total Enterprise Value
$3.44B
Earnings Per Share
$-7.27
Revenue
$66.5M
Net Profit
$-348M
EBITDAMargin
-527.84%
EBITDA
$-351M
Enterprise Value / Sales
51.77x
Debt TEV
0.03x
TEVNet Income
-9.9x
Total Debt
$95.9M
Total Equity
$464M
Three Year Compounded Annual Growth Rate Of Revenue
33.79%
Non-Profit Donations & Grants
$20K - $100K
2018
$20K - $100K
2017
$5,000 - $10K
2016
Investors
Details Hidden

Founder, President & Chief Executive Officer at Frontier Medicines

Details Hidden

Former Chief Scientific Officer at Blueprint Medicines Corp.

Details Hidden

Director at Oregon Health & Science University - Knight Cancer Institute

Suppliers
Forest City Realty Trust, Inc. Trusts & Funds | Cleveland, OH

Forest City Realty Trust, Inc. engages in the provision of real estate investment. Its activities include ownership, development, management, and acquisition of commercial and residential real estate throughout the United States. The firm's project portfolio consists of apartment properties, build-to-suit buildings, and regional and urban retail centers. The company was founded by Charles Ratner, Max, Ratner, Leonard Ratner and Fannye Ratner in 1920 and is headquartered in Cleveland, OH.

Catalent, Inc. Other Business & Consulting Services | Somerset, NJ

Catalent, Inc. operates as a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale manufacturing of oral solid dose forms for pharmaceutical and consumer health markets, and supporting ancillary services. The Biologics segment provides biologic cell-line, cell therapy and viral vector gene therapy development and manufacturing; formulation, development, and manufacturing for parenteral dose forms, which include prefilled syringes, vials, and cartridges; and analytical development and testing services for large molecules. The Oral and Speciality Delivery segment provides advanced formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment provides manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics in clinical trials. The company was founded in 1933 and is headquartered in Somerset, NJ.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Roche Holding AG Pharmaceuticals - Basel, Switzerland

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Blueprint Medicines Corp.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Blueprint Medicines Corp.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Blueprint Medicines Corp..